Lexicon Pharmaceuticals, Inc.
LXRX· Nasdaq
Filed Mar 10, 2022 · 10-K · 69 days after period end · 0001062822-22-000005
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $23.37M | $8.73M | -$41.83M |
| Net Income | -$25.61M | -$5.50M | -$51.14M | -$28.38M |
| EPS Diluted | — | — |
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
| -$0.48 |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Mar 10, 2022 · 69 d after period end